Table 1 Clinical characteristics of eleven patients with systemic sclerosis undergoing blood oxygenation level-dependent MRI of the calf muscles
From: Impaired skeletal muscle microcirculation in systemic sclerosis
Characteristic | Value |
|---|---|
SSc disease characteristics | |
SSc duration by first non-Raynaud's symptom, mean (years) | 5.4, SD 5.0 |
SSc duration by onset of Raynaud's phenomenon, mean (years) | 6.8, SD 6.2 |
Diffuse cutaneous SSc, n | 3 |
Limited cutaneous SSc, n | 5 |
Other SSc, n | 3 |
Modified Rodnan skin score, median | 5, range 1-26 |
Antinuclear autoantibody positive, n | 11 |
Anti-centromere autoantibodies positive, n | 3 |
Anti-topoisomerase autoantibodies positive, n | 5 |
PM-Scl autoantibodies positive, n | 1 |
Erythrocyte sedimentation rate, mean (mm) | 14, SD 12 |
Muscle parameters | |
Serum creatine kinase elevation, n | 2 |
Muscle atrophy, n | 1 |
Muscle weakness on manual muscle testing, n | 1 |
Six-minute walk test distance, mean (meters) | 449, SD 68 |
Cardiopulmonary function | |
Systolic blood pressure, mean (mmHg) | 127, SD 17 |
Diastolic blood pressure, mean (mmHg) | 78, SD 11 |
Systolic pulmonary arterial pressure by echocardiography, mean (mmHg) | 23.7, SD 4.4 |
Forced vital capacity, mean % of normal | 91.4, SD 18.6 |
Diffusing capacity of the lung for carbon monoxide, mean % of normal | 73.1, SD 26.3 |
SSc therapy | |
Patients on prednisone, n | 5 |
Patients on methotrexate, azathioprine, mycophenolate, or cyclophosphamide, n | 7 |